Floatz logo

Evofosfamide

High-risk Myelodysplastic Syndrome

Threshold PharmaceuticalsSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

315 Active assets in the High-risk Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Fludarabine
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Evofosfamide is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
63 / 100
View asset →
pancreatic neoplasmDormant
B
Indicative ·
56 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →